DigiTwin (tm)/ ML-based Adherence & Chronic Management at scale - Personalized & Predictive Digital Therapeutics
Reference number | |
Coordinator | Care4 Health Management AB |
Funding from Vinnova | SEK 300 000 |
Project duration | March 2019 - August 2019 |
Status | Completed |
Venture | Innovative Startups |
Call | Innovative Startups step 1 spring 2019 |
Important results from the project
En följsamhets-MVP, dvs teknik, UX och kommersiell validering har utvecklats som en första prototyp modul under den detta grant. Investerare har nu visat intresse för Care4s affärsplan, dock krävs högre TRL-mognad vilket detta grant möjlig-gjort som en första del-etapp. Delar av den tekniska MVPn har framgångsrikt presenterades under Almedalsveckan samt till två kommersiella partner, som nu vill gå vidare under NDA till nästa nivå av validering och fortsatt stablisering/datamässigt av den tekniska MVPn + grant nr 2 inom innovativa startups med tydligt mål.
Expected long term effects
A compliance MVP, ie technology, UX and partial commercial validation is executed within this grant. Investors have now shown interest in Care4´s business plan, but require higher TRL maturity, which this grant has allowed for a first stage. Parts of the technical MVP have been successfully presented during the Almedals week as well as to two commercial partners, who now want to proceed under the NDA to the next level of validation and continued stabilization/data-based of the technical MVP within grant 2 with clearly developed spec to apply for during innovative startups next grant.
Approach and implementation
Care4 has developed and validated a basic MVP of the intelligent digital therapeutics software. The mission is to offer preventive, personalized and precision-based healthcare recommendations to keep patients healthier by personalized interventions. After the first technical validation driven two first milestones are reached a simplistic UX and initial user-testing validation on the MVP is planned to be executed together with representative patients and clinics on a consent basis with diabetes patients as the focus.